A Phase 1, Randomized, Parallel-Design, Open-Label Study to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy Volunteers

Trial Profile

A Phase 1, Randomized, Parallel-Design, Open-Label Study to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2015

At a glance

  • Drugs Etanercept (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Adverse reactions
  • Sponsors Protalix Biotherapeutics
  • Most Recent Events

    • 05 Oct 2015 Results published in Protalix media release.
    • 05 Oct 2015 Status changed from recruiting to completed, as reported by Protalix Bio Therapeutics media release.
    • 07 May 2015 Status changed from planning to recruiting, as reported by Portalix Bio Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top